FinAd research workflow
finad.shardingsmeet.com
LoginSign up
Research mode active. Personalized investment actions require suitability and advisor approval.

FinAd is in research and education mode by default. Outputs are probabilistic research signals, not guaranteed returns or personalized investment advice.

Personalized investment recommendations for Indian securities must be reviewed and approved by a SEBI-registered investment adviser or authorized expert workflow before being shown as advice.

NSE:ZYDUSLIFE

Zydus Lifesciences

Healthcare / Healthcare. Analysis combines daily candles, derived indicators, fundamentals, news intelligence, and review-gated recommendations.

quality
65
momentum
73
valuation
35
news
50
liquidity
70
risk
51

Recommendations by horizon

NSE:ZYDUSLIFE / 20D

Zydus Lifesciences

momentum-trend
HOLDResearch mode
Confidence60/100
Risk51/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 978.45 - 999.82 around confirmed liquidity
Invalidation: 927.73
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0
NSE:ZYDUSLIFE / 6M

Zydus Lifesciences

balanced-ai-blend
HOLDAdvisor approved
Confidence53/100
Risk51/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 970.68 - 999.82 around confirmed liquidity
Invalidation: 927.73
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0
NSE:ZYDUSLIFE / MULTI_YEAR

Zydus Lifesciences

quality-compounder
HOLDResearch mode
Confidence57/100
Risk51/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 970.68 - 999.82 around confirmed liquidity
Invalidation: 927.73
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0